Cited by 193Drug Transport and Resistance MechanismsAlzheimer's disease research and treatmentsBarrier Structure and Function Studies

The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.

Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood–Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease

Open access

Deo, Anand K., Borson, Soo, Link, Jeanne M., Domino, Karen, Eary, Janet F., Ke, Ban, Richards, Todd L., Mankoff, David A., Minoshima, Satoshi, O’Sullivan, Finbarr, Eyal, Sara, Hsiao, Peng, Maravilla, Ken, Unadkat, Jashvant D.·2014·Journal of Nuclear Medicine

DOI 10.2967/jnumed.113.130161PMC PMC4691246

Open this paper in CoChat — free account Open PDF

Abstract

UNLABELLED: Studies in animals and postmortem human brain tissue support a role for P-glycoprotein in clearance of cerebral β-amyloid across the blood-brain barrier (BBB). We tested the hypothesis that BBB P-glycoprotein activity is diminished in Alzheimer disease (AD) by accounting for an AD-related reduction in regional cerebral blood flow (rCBF). METHODS: We compared P-glycoprotein activity in mild-AD patients (n = 9) and cognitively normal, age-matched controls (n = 9) using PET with a labeled P-glycoprotein substrate, (11)C-verapamil, and (15)O-water to measure rCBF. BBB P-glycoprotein activity was expressed as the (11)C-verapamil radioactivity extraction ratio ((11)C-verapamil brain distributional clearance, K1/rCBF). RESULTS: Compared with controls, BBB P-glycoprotein activity was significantly lower in the parietotemporal, frontal, and posterior cingulate cortices and hippocampus of mild AD subjects. CONCLUSION: BBB P-glycoprotein activity in brain regions affected by AD is reduced and is independent of rCBF. This study improves on prior work by eliminating the confounding effect that reduced rCBF has on assessment of BBB P-glycoprotein activity and suggests that impaired P-glycoprotein activity may contribute to cerebral β-amyloid accumulation in AD. P-glycoprotein induction or activation to increase cerebral β-amyloid clearance could constitute a novel preventive or therapeutic strategy for AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2967/jnumed.113.130161

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single subject brain
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Nonparametric permutation tests for functional neuroimaging: A primer with examples
Nichols, T. E., & Holmes, A. P. (2002) · Human Brain Mapping · doi:10.1002/hbm.1058 · Cited by 6,256
Alzheimer’s disease
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802
Self-citation
A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET.
(1995) · PubMed Central · doi:10.2967/jnumed.120.252510a · Cited by 996
Self-citation
Brain glucose metabolism in the early and specific diagnosis of Alzheimer?s disease
Mosconi, L. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1762-7 · Cited by 938
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M. F., Fritz, P., Kreichgauer, H. P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917

Show all 43 references

Sorted by citations

Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
The role of brain vasculature in neurodegenerative disorders
Sweeney, M. D., Kisler, K., Montagne, A., Toga, A. W., & Zlokovic, B. V. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0234-x · Cited by 998
Alzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672
Impact of Metabolic Syndrome on Neuroinflammation and the Blood–Brain Barrier
Dyken, P. C. V., & Lacoste, B. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00930 · Cited by 377
Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier
Li, J., Zheng, M., Shimoni, O., Banks, W. A., Bush, A. I., Gamble, J. R., & Shi, B. (2021) · Advanced Science · doi:10.1002/advs.202101090 · Cited by 202
Dysfunction of the blood–brain barrier in Alzheimer's disease: Evidence from human studies
Kurz, C., Walker, L., Rauchmann, B., & Perneczky, R. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12782 · Cited by 183
“Two published studies showed a decreased binding potential of the Aβ carrier P-gp in AD patients compared with controls(88,89) in disease-specific regions (parietotemporal, frontal, posterior cingulate cortices and hippocampus).(89)”
Result
Neuronal Activity Regulates Blood-Brain Barrier Efflux Transport through Endothelial Circadian Genes
Pulido, R. S., Munji, R. N., Chan, T. C., Quirk, C. R., Weiner, G., Weger, B. D., Rossi, M., Elmsaouri, S., Malfavon, M., Deng, A., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.09.002 · Cited by 178
Neuroinflammation in Alzheimer's Disease
Sawikr, Y., Yarla, N. S., Peluso, I., Kamal, M. A., Aliev, G., & Bishayee, A. (2017) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2017.02.001 · Cited by 161
Blood–brain barrier link to human cognitive impairment and Alzheimer’s disease
Barisano, G., Montagne, A., Kisler, K., Schneider, J. A., Wardlaw, J. M., & Zlokovic, B. V. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-021-00014-4 · Cited by 157
Stem cell therapy for Alzheimer's disease
Liu, X., Yang, L.-P., & Zhao, L. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i8.787 · Cited by 162
Regulation of ABC Transporters Blood–Brain Barrier
Miller, D. S. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2014.10.002 · Cited by 146
Current and emerging avenues for Alzheimer's disease drug targets
Loera‐Valencia, R., Cedazo-Mínguez, Á., Kenigsberg, P.-A., Page, G., Duarte, A. I., Giusti, P., Zusso, M., Robert, P. H., Frisoni, G. B., Cattaneo, A., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12959 · Cited by 142
Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics
Pan, Y., & Nicolazzo, J. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.009 · Cited by 131
Is Alzheimer’s Disease a Liver Disease of the Brain?
Bassendine, M. F., Taylor-Robinson, S. D., Fertleman, M., Khan, M., & Neely, D. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-190848 · Cited by 124
Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain
Zhao, L., Li, Z., Vong, J. S. L., Chen, X., Lai, H. M., Yan, L. Y. C., Huang, J., Sy, S. K. H., Tian, X. Y., Huang, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18249-3 · Cited by 125
Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches
Guo, Y., Chu, X., Parrott, N. J., Brouwer, K. L. R., Hsu, V., Nagar, S., Matsson, P., Sharma, P. K., Snoeys, J., Sugiyama, Y., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1183 · Cited by 122
Self-citation
Blood-brain barrier dysfunction and Alzheimer’s disease: associations, pathogenic mechanisms, and therapeutic potential
Chen, Y., He, Y., Han, J., Wei, W., & Chen, F. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1258640 · Cited by 116
Approaches to CNS Drug Delivery with a Focus on Transporter-Mediated Transcytosis
Razzak, R. A., Florence, G. J., & Gunn‐Moore, F. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123108 · Cited by 118
A Role for P-Glycoprotein in Clearance of Alzheimer Amyloid ? -Peptide from the Brain
Wang, W., M. Bodles-Brakhop, A., & W. Barger, S. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160314151012 · Cited by 107
Aβ40 Reduces P-Glycoprotein at the Blood–Brain Barrier through the Ubiquitin–Proteasome Pathway
Hartz, A. M. S., Zhong, Y., Wolf, A. M., LeVine, H., Miller, D. S., & Bauer, B. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0350-15.2016 · Cited by 100
The blood–brain barrier: a help and a hindrance
Rust, R., Yin, H. R., Buil, B. A., Sagare, A. P., & Kisler, K. (2025) · Brain · doi:10.1093/brain/awaf068 · Cited by 109
P‐glycoprotein: a role in the export of amyloid‐β in Alzheimer's disease?
Chai, A. B., Leung, G. K. F., Callaghan, R., & Gelissen, I. C. (2019) · FEBS Journal · doi:10.1111/febs.15148 · Cited by 100
ABC Transporters Are Key Players in Alzheimer’s Disease
Pereira, C. D., Martins, F., Wiltfang, J., Silva, O. A. B. D. C. E., & Rebelo, S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170639 · Cited by 94
Resveratrol and Amyloid-Beta: Mechanistic Insights
Jia, Y., Wang, N., & Liu, X. (2017) · Nutrients · doi:10.3390/nu9101122 · Cited by 93
Altered Brain Endothelial Cell Phenotype from a Familial Alzheimer Mutation and Its Potential Implications for Amyloid Clearance and Drug Delivery
Oikari, L. E., Pandit, R., Stewart, R., Cuní‐López, C., Quek, H., Sutharsan, R., Rantanen, L. M., Oksanen, M., Lehtonen, Š., de Boer, C. M., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.03.011 · Cited by 87
Neural stem cell therapy for neurovascular injury in Alzheimer's disease
Boese, A. C., Hamblin, M. H., & Lee, J. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113112 · Cited by 89
In vivo methods for imaging blood–brain barrier function and dysfunction
Harris, W. J., Asselin, M., Hinz, R., Parkes, L. M., Allan, S. M., Schießl, I., Boutin, H., & Dickie, B. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05997-1 · Cited by 91
Therapeutic role of rifampicin in Alzheimer's disease
Yuluğ, B., Hanoğlu, L., Ozansoy, M., Isık, D., Kılıç, Ü., Kılıç, E., & Schabitz, W. R. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12637 · Cited by 81
Pharmacokinetic and pharmacodynamic alterations in older people with dementia
Reeve, E., Trenaman, S. C., Rockwood, K. J., & Hilmer, S. N. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1325873 · Cited by 87
Interindividual and Regional Variability in Drug Transporter Abundance at the Human Blood–Brain Barrier Measured by Quantitative Targeted Proteomics
Billington, S., Salphati, L., Hop, C. E. C. A., Chu, X., Evers, R., Burdette, D., Rowbottom, C., Lai, Y.-R., Xiao, G.-Q., Humphreys, W. G., et al. (2019) · Clinical pharmacology and therapy · doi:10.1002/cpt.1373 · Cited by 70
Self-citation
Age-Related Functional and Expressional Changes in Efflux Pathways at the Blood-Brain Barrier
Erdő, F., & Krajcsi, P. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00196 · Cited by 80
The microcirculation, the blood-brain barrier, and the neurovascular unit in health and Alzheimer disease: The aberrant pericyte is a central player
Divecha, Y. A., Rampes, S., Tromp, S., Boyanova, S., Fleckney, A. L., Fidanboylu, M., & Thomas, S. A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100052 · Cited by 83
Alterations in drug disposition in older adults: a focus on geriatric syndromes
Maher, D., Ailabouni, N. J., Mangoni, A. A., Wiese, M. D., & Reeve, E. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1839413 · Cited by 74
Imaging techniques to study drug transporter function in vivo
Tournier, N., Stieger, B., & Langer, O. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.006 · Cited by 76
The restorative role of annexin A1 at the blood–brain barrier
McArthur, S., Loiola, R. A., Maggioli, E., Errede, M., Virgintino, D., & Solito, E. (2016) · Fluids and Barriers of the CNS · doi:10.1186/s12987-016-0043-0 · Cited by 73
Dissecting the Contribution of Vascular Alterations and Aging to Alzheimer’s Disease
Janota, C. S., Lemere, C. A., & Brito, M. A. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9319-7 · Cited by 70
Rapid in vivo measurement of β-amyloid reveals biphasic clearance kinetics in an Alzheimer’s mouse model
Yuede, C. M., Lee, H. J., Restivo, J. L., Davis, T. A., Hettinger, J. C., Wallace, C. E., Young, K. L., Hayne, M. R., Bu, G., Li, C.-Z., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151428 · Cited by 65
Contribution of Gut Microbiota to Immunological Changes in Alzheimer’s Disease
van Olst, L., Roks, S. J. M., Kamermans, A., Verhaar, B. J. H., van der Geest, A. M., Muller, M., van der Flier, W. M., & de Vries, H. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.683068 · Cited by 68
Reconsidering the role of blood-brain barrier in Alzheimer’s disease: From delivery to target
Sousa, J. A., Bernardes, C., Bernardo-Castro, S., Lino, M. M., Albino, I., Ferreira, L., Brás, J., Guerreiro, R. J., Tábuas‐Pereira, M., Baldeiras, I., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1102809 · Cited by 67
Blood-brain barrier transporters: An overview of function, dysfunction in Alzheimer’s disease and strategies for treatment
Chaves, J. C. S., Dando, S. J., White, A. R., & Oikari, L. E. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166967 · Cited by 62
Innate immune sensors and regulators at the blood brain barrier: focus on toll-like receptors and inflammasomes as mediators of neuro-immune crosstalk and inflammation
Acıoğlu, Ç., & Elkabes, S. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03360-3 · Cited by 67
Abundance of P‐Glycoprotein and Other Drug Transporters at the Human Blood‐Brain Barrier in Alzheimer’s Disease: A Quantitative Targeted Proteomic Study
Storelli, F., Billington, S. F., Kumar, A. R., & Unadkat, J. D. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2035 · Cited by 60
Self-citation
Region-specific blood–brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer’s disease
Sekhar, G. N., Fleckney, A. L., Boyanova, S., Rupawala, H., Lo, R., Wang, H., Farag, D. B., Rahman, K. M., Broadstock, M., Reeves, S., et al. (2019) · Fluids and Barriers of the CNS · doi:10.1186/s12987-019-0158-1 · Cited by 57
Preventing P-gp Ubiquitination Lowers Aβ Brain Levels in an Alzheimer’s Disease Mouse Model
Hartz, A. M. S., Zhong, Y., Shen, A. N., Abner, E. L., & Bauer, B. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00186 · Cited by 54
The impact of ATP-binding cassette transporters in the diseased brain: Context matters
Baltira, C., Aronica, E., Elmquist, W. F., Langer, O., Löscher, W., Sarkaria, J. N., Wesseling, P., de Gooijer, M. C., & van Tellingen, O. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101609 · Cited by 54
Factors Governing P-Glycoprotein-Mediated Drug–Drug Interactions at the Blood–Brain Barrier Measured with Positron Emission Tomography
Wanek, T., Römermann, K., Mairinger, S., Stanek, J., Sauberer, M., Filip, T., Traxl, A., Kuntner, C., Pahnke, J., Bauer, F., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00168 · Cited by 49
Induced expression of P-gp and BCRP transporters on brain endothelial cells using transferrin functionalized nanostructured lipid carriers: A first step of a potential strategy for the treatment of Alzheimer’s disease
Arduino, I., Iacobazzi, R. M., Riganti, C., Lopedota, A., Perrone, M. G., Lopalco, A., Cutrignelli, A., Cantore, M., Laquintana, V., Franco, M., et al. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120011 · Cited by 47
Alteration in the Function and Expression of SLC and ABC Transporters in the Neurovascular Unit in Alzheimer’s Disease and the Clinical Significance
Jia, Y., Wang, N., Zhang, Y., Xue, D., Lou, H., & Liu, X. (2020) · Aging and Disease · doi:10.14336/ad.2019.0519 · Cited by 50
Brain‐targeting drug delivery systems
Liu, P., & Jiang, C. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1818 · Cited by 47
Drug Access to the Central Nervous System in Alzheimer’s Disease: Preclinical and Clinical Insights
Mehta, D. C., Short, J. L., Hilmer, S. N., & Nicolazzo, J. A. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1522-0 · Cited by 47
Efflux proteins at the blood–brain barrier: review and bioinformatics analysis
Saidijam, M., Dermani, F. K., Sohrabi, S., & Patching, S. G. (2017) · Xenobiotica · doi:10.1080/00498254.2017.1328148 · Cited by 48
The validity of 18F-GE180 as a TSPO imaging agent
Zanotti-Fregonara, P., Veronese, M., Pascual, B., Rostomily, R., Turkheimer, F., & Masdeu, J. C. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-4268-4 · Cited by 45
Dysfunction of the neurovascular unit in diabetes-related neurodegeneration
Yan, C., Zhou, Y., Chen, Q., Luo, Y., Zhang, J. H., Huang, H., & Shao, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110656 · Cited by 47
Altered cerebral blood flow in older adults with Alzheimer’s disease: a systematic review
Swinford, C. G., Risacher, S. L., Wu, Y., Apostolova, L. G., Gao, S., Bice, P. J., & Saykin, A. J. (2022) · Brain Imaging and Behavior · doi:10.1007/s11682-022-00750-6 · Cited by 44
Biomarkers Assessing Endothelial Dysfunction in Alzheimer’s Disease
Custodia, A., Aramburu-Núñez, M., Rodríguez‐Arrizabalaga, M., Peleteiro, J. M. P., Vázquez‐Vázquez, L., Camino-Castiñeiras, J., Aldrey, J. M., Castillo, J., Ouro, A., Sobrino, T., et al. (2023) · Cells · doi:10.3390/cells12060962 · Cited by 47
Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study
Liu, L., Collier, A. C., Link, J. M., Domino, K. B., Mankoff, D. A., Eary, J. F., Spiekerman, C. F., Hsiao, P., Deo, A. K., & Unadkat, J. D. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058685 · Cited by 45
Self-citation
Blood-brain barrier integrity in a mouse model of Alzheimer's disease with or without acute 3D6 immunotherapy
Gustafsson, S. S., Gustavsson, T., Roshanbin, S., Hultqvist, G., Hammarlund‐Udenaes, M., Sehlin, D., & Syvänen, S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.001 · Cited by 44
Transport of Alzheimer’s associated amyloid-β catalyzed by P-glycoprotein
McCormick, J. W., McCormick, L. A., (党陈), G. C., Vogel, P. D., & Wise, J. G. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250371 · Cited by 43
Endothelial Progenitor Cells and Vascular Alterations in Alzheimer’s Disease
Custodia, A., Ouro, A., Romaus‐Sanjurjo, D., Peleteiro, J. M. P., de Vries, H. E., Castillo, J., & Sobrino, T. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.811210 · Cited by 45
Diagnostic biomarkers in Alzheimer’s disease
Andersen, E., Casteigne, B., Chapman, W. D., Creed, A., Foster, F., Lapins, A., Shatz, R., & Sawyer, R. P. (2021) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2021.100041 · Cited by 42
Intact blood-brain barrier transport of small molecular drugs in animal models of amyloid beta and alpha-synuclein pathology
Gustafsson, S. S., Lindström, V., Ingelsson, M., Hammarlund‐Udenaes, M., & Syvänen, S. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.002 · Cited by 39
Imaging blood–brain barrier disruption in neuroinflammation and Alzheimer’s disease
Lee, R., & Funk, K. E. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1144036 · Cited by 42
Effect of P‐glycoprotein inhibition at the blood–brain barrier on brain distribution of (R)‐[11C]verapamil in elderly vs. young subjects
Bauer, M., Wulkersdorfer, B., Karch, R., Philippe, C., Jäger, W. R., Stanek, J., Wadsak, W., Hacker, M., Zeitlinger, M. A., & Langer, O. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13301 · Cited by 36
Protecting P-glycoprotein at the blood–brain barrier from degradation in an Alzheimer’s disease mouse model
Ding, Y., Zhong, Y., Baldeshwiler, A., Abner, E. L., Bauer, B., & Hartz, A. M. S. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-021-00245-4 · Cited by 35
Imaging P-Glycoprotein Induction at the Blood–Brain Barrier of a β-Amyloidosis Mouse Model with 11C-Metoclopramide PET
Zoufal, V., Mairinger, S., Brackhan, M., Krohn, M., Filip, T., Sauberer, M., Stanek, J., Wanek, T., Tournier, N., Bauer, M., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.237198 · Cited by 36
Clinical Applications of Simultaneous PET/MR Imaging Using (R)-[11C]-Verapamil with Cyclosporin A: Preliminary Results on a Surrogate Marker of Drug-Resistant Epilepsy
Shin, J.-W., Chu, K., Shin, S. A., Jung, K., Lee, S., Lee, Y., Moon, J., Lee, D. Y., Lee, J. S., Lee, D. S., et al. (2015) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4566 · Cited by 34
The Blood-Brain Barrier in Alzheimer’s Disease
Storck, S. E., Hartz, A. M. S., & Pietrzik, C. U. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_418 · Cited by 31
Rationalising the role of Keratin 9 as a biomarker for Alzheimer’s disease
Richens, J. L., Spencer, H. L., Butler, M., Cantlay, F., Vere, K., Bajaj, N. P. S., Morgan, K., & O’Shea, P. (2016) · Scientific Reports · doi:10.1038/srep22962 · Cited by 34
Radiopharmaceuticals for assessing ABC transporters at the blood–brain barrier
Raaphorst, R. M., Windhorst, A. D., Elsinga, P. H., Colabufo, N., Lammertsma, A. A., & Luurtsema, G. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.73 · Cited by 29
Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood–Brain Barrier
Savolainen, H., Cantore, M., Colabufo, N. A., Elsinga, P. H., Windhorst, A. D., & Luurtsema, G. (2015) · Molecular Pharmaceutics · doi:10.1021/mp5008103 · Cited by 31
Discerning the Role of Blood Brain Barrier Dysfunction in Alzheimer’s Disease
Tao, Q., Lin, R.-R., Chen, Y.-H., & Wu, Z. (2022) · Aging and Disease · doi:10.14336/ad.2022.0130-1 · Cited by 34
Cerebral ABC Transporter-common Mechanisms May Modulate Neurodegenerative Diseases and Depression in Elderly Subjects
Pahnke, J., Fröhlich, C., Paarmann, K., Krohn, M., Bogdanović, N., Årsland, D., & Winblad, B. G. (2014) · Archives of Medical Research · doi:10.1016/j.arcmed.2014.10.010 · Cited by 30
Effects of whole-brain radiation therapy on the blood–brain barrier in immunocompetent and immunocompromised mouse models
Blethen, K. E., Sprowls, S. A., Arsiwala, T. A., Wolford, C. P., Panchal, D. M., Fladeland, R. A., Glass, M. J., Dykstra, L. P., Kielkowski, B. N., Blackburn, J. R., et al. (2023) · Radiation Oncology · doi:10.1186/s13014-023-02215-6 · Cited by 34
Altered Expression of Small Intestinal Drug Transporters and Hepatic Metabolic Enzymes in a Mouse Model of Familial Alzheimer’s Disease
Pan, Y., Omori, K., Ali, I., Tachikawa, M., Terasaki, T., Brouwer, K. L. R., & Nicolazzo, J. A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00500 · Cited by 30
Transporter Regulation in Critical Protective Barriers: Focus on Brain and Placenta
Taggi, V., Riera‐Romo, M., Piquette‐Miller, M., zu Schwabedissen, H. E. M., & Neuhoff, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071376 · Cited by 30
Proteasome inhibition protects blood–brain barrier P-glycoprotein and lowers Aβ brain levels in an Alzheimer’s disease model
Vulin, M., Zhong, Y., Maloney, B. J., Bauer, B., & Hartz, A. M. S. (2023) · Fluids and Barriers of the CNS · doi:10.1186/s12987-023-00470-z · Cited by 28
Effect of Structural Modifications to Glyoxal-bis(thiosemicarbazonato)copper(II) Complexes on Cellular Copper Uptake, Copper-Mediated ATP7A Trafficking, and P-Glycoprotein Mediated Efflux
Acevedo, K. M., Hayne, D. J., McInnes, L. E., Noor, A., Duncan, C., Moujalled, D., Volitakis, I., Rigopoulos, A., Barnham, K. J., Villemagne, V. L., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01158 · Cited by 27
Measurement of cerebral ABCC1 transport activity in wild-type and APP/PS1-21 mice with positron emission tomography
Zoufal, V., Mairinger, S., Krohn, M., Wanek, T., Filip, T., Sauberer, M., Stanek, J., Kuntner, C., Pahnke, J., & Langer, O. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19854541 · Cited by 26
Cutting-edge Strategies for Overcoming Therapeutic Barriers in Alzheimer's Disease
Inamdar, A., Gurupadayya, B., Halagali, P., Nandakumar, S., Pathak, R., Singh, H., & Sharma, H. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128344571241018154506 · Cited by 33
Lack of Interactions Between an Antisense Oligonucleotide with 2′- O -(2-Methoxyethyl) Modifications and Major Drug Transporters
Yu, R. Z., Warren, M. S., Watanabe, T. A., Nichols, B., Jahic, M., Huang, J., Burkey, J., Geary, R. S., Henry, S. P., & Wang, Y. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0588 · Cited by 26
Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET
Zoufal, V., Wanek, T., Krohn, M., Mairinger, S., Filip, T., Sauberer, M., Stanek, J., Pekar, T., Bauer, M., Pahnke, J., et al. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18806640 · Cited by 26
Molecular Imaging of Membrane Transporters’ Activity in Cancer: a Picture is Worth a Thousand Tubes
Mann, A., Semenenko, I., Meir, M., & Eyal, S. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9752-6 · Cited by 25
Self-citation
Challenges and Perspectives of the Hybridization of PET with Functional MRI or Ultrasound for Neuroimaging
Tournier, N., Comtat, C., Lebon, V., & Gennisson, J. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.10.015 · Cited by 25
Fibrin-targeting immunotherapy for dementia
Kantor, A. B., Akassoglou, K., & Stavenhagen, J. B. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.105 · Cited by 24
Selective neuronal vulnerability in Alzheimer’s disease
Wang, Z.-T., Zhang, C. M., Wang, Y., Dong, Q., Tan, L., & Yu, J. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101114 · Cited by 24
Copper bis(thiosemicarbazone) complexes modulate P‐glycoprotein expression and function in human brain microvascular endothelial cells
Pyun, J., McInnes, L. E., Donnelly, P. S., Mawal, C., Bush, A. I., Short, J. L., & Nicolazzo, J. A. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15609 · Cited by 23
Underlying Mechanisms and Treatment of Cellular Senescence-Induced Biological Barrier Interruption and Related Diseases
Sun, R., Feng, J., & Wang, J. (2023) · Aging and Disease · doi:10.14336/ad.2023.0621 · Cited by 28
Amyloid-β Precursor Protein Modulates the Sorting of Testican-1 and Contributes to Its Accumulation in Brain Tissue and Cerebrospinal Fluid from Patients with Alzheimer Disease
Barrera-Ocampo, A. A., Arlt, S., Matschke, J., Hartmann, U., Puig, B., Ferrer, I., Zürbig, P., Glatzel, M., Falla, D. S., & Jahn, H. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw065 · Cited by 23
Contributions of Drug Transporters to Blood-Brain Barriers
Liu, L., & Liu, X. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7647-4_9 · Cited by 21
Vascular endothelial cells: a fundamental approach for brain waste clearance
Wei, H., Jiang, H., Zhou, Y., Xiao, X., Zhou, C., & Ji, X. (2022) · Brain · doi:10.1093/brain/awac495 · Cited by 20
Neurovascular Alterations in Alzheimer’s Disease: Transporter Expression Profiles and CNS Drug Access
McInerney, M. P., Short, J. L., & Nicolazzo, J. A. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0077-5 · Cited by 20
Role of the gut microbiome in Alzheimer’s disease
Chok, K. C., Ng, K. Y., Koh, R. Y., & Chye, S. M. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0122 · Cited by 22
Alterations in Expression and Function of ABC Family Transporters at Blood-Brain Barrier under Liver Failure and Their Clinical Significances
Fan, Y., & Liu, X. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030102 · Cited by 20
ABC efflux transporters at blood-central nervous system barriers and their implications for treating spinal cord disorders
Koehn, L. M. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.272568 · Cited by 19
MC225, a Novel Probe for P-glycoprotein PET Imaging at the Blood–brain Barrier: In Vitro Cardiovascular Safety Evaluation
Fusi, F., Durante, M., Gorelli, B., Perrone, M. G., Colabufo, N. A., & Saponara, S. (2017) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000536 · Cited by 19
Nanomedicine against Alzheimer’s and Parkinson’s Disease
Tandon, A., Singh, S. J., & Chaturvedi, R. K. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201021140904 · Cited by 20
Quantification of P-glycoprotein function at the human blood-brain barrier using [18F]MC225 and PET
Mossel, P., Arif, W. M., de Souza, G. S., García-Varela, L., van der Weijden, C. W. J., Boersma, H. H., Willemsen, A. T. M., Boellaard, R., Elsinga, P. H., Borra, R., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06363-5 · Cited by 21
Ionophore and Biometal Modulation of P-glycoprotein Expression and Function in Human Brain Microvascular Endothelial Cells
McInerney, M. P., Volitakis, I., Bush, A. I., Banks, W. A., Short, J. L., & Nicolazzo, J. A. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2377-6 · Cited by 18
Towards a better diagnosis and treatment of dementia: Identifying common and distinct neuropathological mechanisms in Alzheimer's and vascular dementia
Vollhardt, A., Frölich, L., Stockbauer, A., Danek, A., Schmitz, C., & Wahl, A.-S. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106845 · Cited by 18

Authors: Deo, A. K., Borson, S., Link, J. M., Domino, K., Eary, J. F., Ke, B., Richards, T. L., Mankoff, D. A., Minoshima, S., O’Sullivan, F., Eyal, S., Hsiao, P., Maravilla, K., & Unadkat, J. D.
Affiliations: University of Washington (US)
ORCID: Deo, Anand K.
Link, Jeanne M.
Domino, Karen
Eary, Janet F.
Richards, Todd L.
Mankoff, David A.
Minoshima, Satoshi
O’Sullivan, Finbarr
Eyal, Sara
Unadkat, Jashvant D.
Venue: Journal of Nuclear Medicine
Publisher: Society of Nuclear Medicine
Published: 2014-05-19
Volume: 55
Issue: 7
Pages: 1106-1111
ISSN: 0161-5505 (ISSN-L)
2159-662X
DOI: 10.2967/jnumed.113.130161
PMC: PMC4691246
OpenAlex: W2130945756
Cited by: 193
References: 43
Citations by year: 2026: 8 · 2025: 14 · 2024: 8 · 2023: 28 · 2022: 17 · 2021: 16 · 2020: 25 · 2019: 16 · 2018: 17 · 2017: 17 · 2016: 13 · 2015: 10 · 2014: 3
FWCI: 6.92
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Nuclear Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: University of Washington
National Institutes of Health (TL1TR000422, UL1TR002319)
National Institute on Aging (AG 031485, R33AG031485)
National Center for Research Resources (TL1RR025016)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords: P-glycoprotein, blood-brain barrier, Alzheimer's disease, amyloid-beta clearance, regional cerebral blood flow, [11C]verapamil, amyloid PET, hippocampus, temporoparietal cortex, frontal cortex, posterior cingulate cortex
MeSH terms: Adult, Aged, Alzheimer Disease, Blood-Brain Barrier, Carbon Radioisotopes, Cerebrovascular Circulation, Female, Humans, Male, Middle Aged, Oxygen Radioisotopes, Verapamil, Water, Case-Control Studies, Amyloid beta-Peptides, ATP Binding Cassette Transporter, Subfamily B, Member 1, Positron-Emission Tomography, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood–Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks